Affordable Access

deepdyve-link
Publisher Website

Might dolutegravir be part of a functional cure for HIV?

Authors
  • Wainberg, Mark A1, 2, 3
  • Han, Ying-Shan1
  • Mesplède, Thibault1
  • 1 a McGill University AIDS Centre, Lady Davis for Medical Research, Jewish General Hospital, Montréal, Que., Canada. , (Canada)
  • 2 b Division of Experimental Medicine, Faculty of Medicine, McGill University, Montréal, Que., Canada. , (Canada)
  • 3 c Department of Microbiology and Immunology, Faculty of Medicine, McGill University, Montréal, Que., Canada. , (Canada)
Type
Published Article
Journal
Canadian Journal of Microbiology
Publisher
Canadian Science Publishing
Publication Date
May 2016
Volume
62
Issue
5
Pages
375–382
Identifiers
DOI: 10.1139/cjm-2015-0725
PMID: 27031127
Source
Medline
Keywords
License
Unknown

Abstract

Antiretroviral therapy (ART) has greatly decreased HIV-related morbidity and mortality. However, HIV can establish viral reservoirs that evade both the immune system and ART. Dolutegravir (DTG) is a second-generation integrase strand transfer inhibitor (INSTI) related to the first-generation INSTIs raltegravir (RAL) and elvitegravir (EVG). DTG shows a higher genetic barrier to the development of HIV-1 resistance than RAL and EVG. More interestingly, clinical resistance mutations to DTG in treatment-naïve patients have not been observed to date. This review summarizes recent studies on strategies toward a cure for HIV, explores resistance profiles of DTG, and discusses how DTG might help in finding a functional cure for HIV.

Report this publication

Statistics

Seen <100 times